cardiovascular benefits of glp 1 agonists GLP-1 Receptor in Heart Failure Management The Cardiovascular Physiology of Glucagon-like
Description
With our commitment to personalized care, we aim to guide our patients through the intricacies of these treatments, highlighting their differences and benefits, and helping them make an informed decision about their health
Karakasis P, Patoulias D, Fragakis N, Mantzoros CS (2025) Effect of glucagon-like peptide1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
34 The trial had a total of 731 patients with a baseline mean A1C of 8.2% and a baseline total daily dose of insulin ranging from 56 to 62 units, depending on the treatment group
Phase III studies are ongoing to further investigate the efficacy and safety of survodutide in obesity management
Recent advances in incretin-based therapy for MASLD: From single to dual or triple incretin receptor agonists
The market for GLP-1 drugs is expanding rapidly
